71 results on '"Toto, Robert D."'
Search Results
2. WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
3. Renal Artery Stenting in Patients on Dialysis: Utility or Futility?
4. Serum Magnesium Levels and Cardiovascular Outcomes in Systolic Blood Pressure Intervention Trial Participants
5. Prediction of Mortality and Major Adverse Kidney Events in Critically Ill Patients With Acute Kidney Injury
6. A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project
7. Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation
8. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
9. The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
10. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
11. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
12. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
13. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
14. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
15. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis
16. Sepsis-Associated Acute Kidney Disease and Long-term Kidney Outcomes
17. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
18. Rationale and design of the Kidney Precision Medicine Project
19. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
20. Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
21. Alport Syndrome Classification and Management
22. Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression
23. Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes: Ready for Prime Time?
24. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
25. Kidney Tubular Damage and Functional Biomarkers in Acute Kidney Injury Following Cardiac Surgery
26. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
27. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
28. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
29. Impact of Acute Kidney Injury and CKD on Adverse Outcomes in Critically Ill Septic Patients
30. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
31. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
32. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
33. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume
34. Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease
35. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
36. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST)
37. The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease
38. Longitudinal Progression Trajectory of GFR Among Patients With CKD
39. Relationship Between Body Mass Index and Proteinuria in Hypertensive Nephrosclerosis: Results From the African American Study of Kidney Disease and Hypertension (AASK) Cohort
40. Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients?
41. Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes
42. Association of Blood Pressure Increases During Hemodialysis With 2-Year Mortality in Incident Hemodialysis Patients: A Secondary Analysis of the Dialysis Morbidity and Mortality Wave 2 Study
43. Validation of Depression Screening Scales in Patients With CKD
44. Prevalence of Major Depressive Episode in CKD
45. Improving Outcomes in Hemodialysis Patients: The Need for Well-Designed Clinical Trials
46. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure
47. Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial
48. Hemodialysis Timing, Survival, and Cardiovascular Outcomes in the Hemodialysis (HEMO) Study
49. Treatment of Hypertension in Chronic Kidney Disease
50. Heart Disease in Diabetic Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.